Updated NETs Clinical Trials

Studies found on ClinicalTrials.gov by a search of: neuroendocrine NOT Melanoma NOT PMS | Recruiting, Not yet recruiting, Available Studies | Phase 2, 3, 4 | Last update posted in the last 30 days
  1. Condition:   Neuroendocrine Carcinomas
    Interventions:   Drug: Folfiri-bevacizumab;   Drug: Folfiri
    Sponsor:   Hospices Civils de Lyon
    Recruiting
  2. Condition:   Neuroendocrine Tumors
    Interventions:   Drug: LEE011;   Drug: everolimus
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Novartis;   Dana-Farber Cancer Institute;   M.D. Anderson Cancer Center
    Recruiting
  3. Conditions:   Metastatic Large Cell Neuroendocrine Carcinoma;   Metastatic Neuroendocrine Carcinoma;   Metastatic Neuroendocrine Neoplasm;   Metastatic Small Cell Carcinoma
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting
  4. Condition:   Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
    Interventions:   Drug: AK105;   Drug: Anlotinib
    Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Not yet recruiting
  5. Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Digestive System Neuroendocrine Neoplasm;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor;   Serotonin-Producing Pancreatic Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  6. Conditions:   Gastroenteropancreatico Tumors;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Olaparib;   Diagnostic Test: Ga dotatate scanning;   Diagnostic Test: FDG-PET scanning
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting
  7. Condition:   Gastroenteropancreatic Neuroendocrine Tumors
    Interventions:   Drug: Somatuline Depot;   Drug: Keytruda
    Sponsors:   Duke University;   Merck Sharp & Dohme Corp.;   Ipsen
    Recruiting
  8. Conditions:   Liver Metastases;   Colorectal Cancer;   Anal Canal Cancer;   Gastrointestinal Neuroendocrine Tumors
    Intervention:   Radiation: SBRT
    Sponsors:   University of Sao Paulo;   Instituto do Cancer do Estado de São Paulo
    Recruiting
  9. Condition:   Neuroendocrine Tumors
    Intervention:   Drug: Satoreotide tetraxetan
    Sponsor:   Ipsen
    Recruiting
  10. Conditions:   Carcinoid Tumor;   Carcinoid Tumor of GI System;   Neuroendocrine Tumors
    Interventions:   Drug: Nivolumab;   Drug: Cabozantinib
    Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb;   Exelixis
    Recruiting
  11. Condition:   Pancreatic Cancer
    Interventions:   Drug: LV5FU2;   Drug: Streptozocin;   Drug: Capecitabine;   Drug: Temozolomide;   Drug: Bevacizumab
    Sponsors:   Gustave Roussy, Cancer Campus, Grand Paris;   National Cancer Institute, France
    Recruiting
  12. Condition:   Gastro-enteropancreatic Neuroendocrine Tumor
    Interventions:   Drug: Lutathera;   Drug: long-acting octreotide;   Drug: high dose long-acting octreotide
    Sponsor:   Advanced Accelerator Applications
    Not yet recruiting
  13. Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  14. Conditions:   Pheochromocytoma;   Paraganglioma;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Ga-68-DOTATATE;   Drug: F-18-FDG;   Drug: Amino Acid solution
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  15. Condition:   Neoplasms
    Interventions:   Drug: Everolimus;   Drug: Sandostatin LAR Depot
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  16. Condition:   SCLC, Extensive Stage
    Intervention:   Drug: Atezolizumab
    Sponsors:   AIO-Studien-gGmbH;   Hoffmann-La Roche
    Recruiting
  17. Conditions:   KRAS Gene Mutation;   Metastatic Colorectal Carcinoma;   NRAS Gene Mutation;   Stage III Colorectal Cancer AJCC v8;   Stage IIIA Colorectal Neuroendocrine Tumor AJCC v8;   Stage IIIB Colorectal Cancer AJCC v8;   Stage IIIC Colorectal Cancer AJCC v8;   Stage IV Colorectal Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8;   Unresectable Carcinoma
    Interventions:   Drug: Binimetinib;   Drug: Palbociclib;   Drug: Trifluridine and Tipiracil Hydrochloride
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting
  18. Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  19. Conditions:   RET-altered Non Small Cell Lung Cancer;   Medullary Thyroid Cancer;   RET-altered Papillary Thyroid Cancer;   RET-altered Colon Cancer;   RET-altered Solid Tumors;   Lung Neoplasm;   Carcinoma, Non-Small-Cell Lung;   Thyroid Diseases;   Thyroid Neoplasm;   Thyroid Cancer, Papillary;   Carcinoma, Neuroendocrine;   Respiratory Tract Neoplasms;   Thoracic Neoplasms;   Neoplasms by Site;   Neoplasms;   Lung Diseases;   Respiratory Tract Disease;   Carcinoma, Bronchogenic;   Bronchial Neoplasms;   Endocrine System Diseases;   Endocrine Gland Neoplasm;   Head and Neck Neoplasms;   Adenocarcinoma, Papillary;   Adenocarcinoma;   Carcinoma;   Neoplasms, Glandular and Epithelial;   Neoplasms by Histologic Type;   Neuroendocrine Tumors;   Neuroectodermal Tumors;   Neoplasms, Germ Cell and Embryonal;   Neoplasms, Nerve Tissue;   Colonic Neoplasms;   Colorectal Neoplasms;   Intestinal Neoplasms;   Gastrointestinal Neoplasms;   Digestive System Neoplasm;   Digestive System Disease;   Gastrointestinal Disease;   Colonic Diseases;   Intestinal Disease
    Intervention:   Drug: pralsetinib (BLU-667)
    Sponsor:   Blueprint Medicines Corporation
    Recruiting
  20. Condition:   Medullary Thyroid Cancer
    Interventions:   Drug: Selpercatinib;   Drug: Cabozantinib;   Drug: Vandetanib
    Sponsors:   Eli Lilly and Company;   Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
    Not yet recruiting
  21. Conditions:   Carcinoma, Non-Small -Cell Lung;   Ovarian Neoplasms;   Small Cell Lung Carcinoma;   Uterine Cervical Neoplasms;   Carcinoma, Neuroendocrine;   Extrapulmonary Small Cell Cancer
    Interventions:   Drug: Topotecan;   Drug: VX-970 (M6620)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  22. Conditions:   Locally Advanced Solid Tumors;   Metastatic Solid Tumors
    Intervention:   Drug: Oral repotrectinib (TPX-0005)
    Sponsor:   Turning Point Therapeutics, Inc.
    Recruiting
  23. Condition:   Advanced Cancer
    Intervention:   Biological: pembrolizumab
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  24. Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  25. Condition:   Breast Cancer
    Interventions:   Drug: alpelisib;   Drug: fulvestrant;   Drug: letrozole;   Drug: Goserelin;   Drug: Leuprolide
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  26. Condition:   Cushing's Syndrome
    Intervention:   Drug: osilodrostat
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  27. Condition:   Merkel Cell Carcinoma
    Intervention:   Drug: KRT-232
    Sponsor:   Kartos Therapeutics, Inc.
    Recruiting
  28. Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
    Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  29. Condition:   Metastatic Merkel Cell Carcinoma
    Intervention:   Drug: INCMGA00012
    Sponsor:   Incyte Corporation
    Recruiting
  30. Conditions:   Metastatic Kidney Medullary Carcinoma;   Metastatic Renal Cell Carcinoma;   SMARCB1 Negative;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8
    Interventions:   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Drug: Ixazomib;   Drug: Ixazomib Citrate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  31. Conditions:   Stage III Merkel Cell Carcinoma AJCC v7;   Stage IIIB Merkel Cell Carcinoma AJCC v7
    Interventions:   Drug: Avelumab;   Other: Laboratory Biomarker Analysis;   Other: Placebo
    Sponsors:   University of Washington;   National Cancer Institute (NCI);   EMD Serono
    Recruiting
  32. Conditions:   Paraganglioma;   Gastrointestinal Stromal Tumors;   Carcinoma, Renal Cell;   Renal Neoplasms;   Pheochromocytoma
    Intervention:   Drug: SGI-110 (guadecitabine)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting